Suhexiang Pill for Acute Ischemic Stroke: A Registry Study (SUNRISE)

Dongzhimen Hospital, Beijing

Status: Enrolling

Conditions: Ischemic Stroke

Treatments: Drug: Suhexiang Pill

Study type: Observational

Funder types: Other

Identifiers

NCT05833932

2021XS-001-05

Details and patient eligibility

About

The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.

Full description

Suhexiang Pill, a traditional Chinese patent medicine, is widely used in China for acute stroke. However, there is a lack of evidence of its efficacy and safety for acute ischemic stroke in real-world setting. This registry study will recruit 1000 patients who receive Suhexiang Pill treatment after acute ischemic stroke.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acute ischemic stroke within 7 days of symptom onset.
• Age ≥ 18
• Patient who has received Suhexiang Pill treatment
• Patient or legally authorized representative has signed informed consent.

Exclusion criteria

• Be allergic to Suhexiang Pill
• Known to be pregnant or breastfeeding.
• With conditions that render outcomes or follow-up unlikely to be assessed.